Edmond de Rothschild

Welcome to our Fund Center

This site provides extensive information about the ranges of Edmond de Rothschild Group funds. In particular, it provides simplified access to key fund-related data (performance, net asset values, features) and their commercial or legal documents.

Please enter your country and indicate which investor category you belong to:
Mobile Logo

EdR Fund Healthcare Thematic equities

Thematic equities
Change in NAV (20/06/2018)
300.95 EUR
Adeline  SALAT-BAROUX–LU1160356694–
Adeline SALAT-BAROUX
Valérie GUELFI–LU1160356694–
Valérie GUELFI
The identity of the managers presented in this document may change during the life of the product.
Risk and reward profile (1)
1234567
Recommended holding period
5 years
300.95 EUR
Change in NAV (20/06/2018)
6
1234567
Risk and reward profile
5 years
Recommended holding period
Change in NAV (20/06/2018)
300.95 EUR
Risk and reward profile
1234567
Recommended holding period
5 years
Adeline SALAT-BAROUX  
Valérie GUELFI  
The identity of the managers presented in this document may change during the life of the product.
Contact

Investment objective

The objective is to grow net assets by investing in companies operating in the healthcare sector, over the recommended investment period.

View more View less

Commentary 31/05/2018

The healthcare sector posted a strong rebound in May. In particular, the fund benefited from gains made by Chinese stocks (Weigao +30% and 3SBio +23%), the US company Momenta, which is developing biosimilars (+18%), and the equipment maker K2M (up +20%). Biotechnology stocks posted a rather mixed performance. Galapagos climbed +15% over the month on the publication of positive clinical trials with its Filgotinib treatment used in various indications (psoriatic arthritis and ulcerative colitis). Genmab fell nearly -20% over the month. The announcement by its partner, Johnson & Johnson, that it was halting Daratumumab trials on lung cancer led to a gross over-correction of the stock. Darzalex, which is produced by Genmab, is a standard treatment for multiple myeloma given its efficacy, especially in combination with Celgene's Revlimid. Sales of Darzalex, which last quarter came to $2 billion annualised, are expected to exceed $5 billion over the next three years. We remain highly confident in Genmab and have taken advantage of this weakness to strengthen our position.

View more View less

Change in NAV

Chart – Base 100 (20/06/2018)
Avertissement
You are about to download the historical data for a portfolio. Please note that past performance is not an indication of future performance and it may vary over time. They may be affected, for example, by changes in exchange rates

Performance R-EUR Cumulative Annualised
Since 01/01/2018

3.48 %

6.65 %

3.48 %

6.65 %

1 Year

-8.00 %

2.68 %

-8.00 %

2.68 %

3 Year

-11.37 %

7.31 %

-3.94 %

2.38 %

5 year

62.25 %

93.90 %

10.16 %

14.15 %

Since inception

200.95 %

253.07 %

12.52 %

14.46 %

Since 01/01/2018 1 Year 3 Year 5 year Since inception
Cumulative

Share class (R-EUR)

Benchmark

3.48 %

6.65 %

-8.00 %

2.68 %

-11.37 %

7.31 %

62.25 %

93.90 %

200.95 %

253.07 %

Annualised

Share class (R-EUR)

Benchmark

-8.00 %

2.68 %

-3.94 %

2.38 %

10.16 %

14.15 %

12.52 %

14.46 %

*Rolling periods

Annual performance



Statistics

VolatilityTracking ErrorCorrelation coefficientInformation ratioSharpe ratio
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*15.96 %14.09 %5.44 %0.94 %-2.04 %0.13 %
3 Year *14.62 %12.76 %5.45 %0.93 %-1.15 %0.05 %
Max. drawdownAlphaBeta
Share class R-EURBenchmarkShare class R-EURBenchmarkShare class R-EURBenchmark
1 Year*-20.31 %-0.22 %1.07 %
3 Year *-25.81 %-0.52 %1.07 %
Max. monthly gain Since inception13.74 %
Max. monthly loss Since inception-17.75 %
Share class R-EUR
Benchmark
1 Year* 3 Year * 1 Year* 3 Year *
Volatility 15.96 % 14.62 % 14.09 % 12.76 %
Tracking Error 5.44 % 5.45 %
Sharpe ratio 0.13 % 0.05 %
Alpha -0.22 % -0.52 %
Correlation coefficient 0.94 % 0.93 %
Information ratio -2.04 % -1.15 %
Max. monthly loss -17.75 %
Max. monthly gain 13.74 %
Max. drawdown -20.31 % -25.81 %
Beta 1.07 % 1.07 %

Fund information

Inception Date (Fund)
30/04/1985
Inception Date (Part)
17/02/2009
Legal form
SICAV
Benchmark
MSCI AC World Health Care (NR)
Currency (fund)
EUR
Currency (share class)
EUR
Distribution Policy
Accumulation
Valuation frequency
Daily
Minimum initial investment
1 Share
ISIN Code
LU1160356694
AuM (fund)
324 M (EUR)
Regulatory authority
CSSF
EU Regulation
UCITS
Management company
Edmond de Rothschild Asset Management (Luxembourg)
Delegated Management Company
Edmond de Rothschild Asset Management (France)
Incorporation
Luxembourg
Maximum management fee
2,100 %
Current management fee
2.100 %
Subscription and redemption conditions
Daily before 12.30 am C.E.T. on day's net asset value
Subscription fee
3.00 % max
Performance fee
15,000 %

Fund documentation

Select all

(1) The rating grades the funds on a scale from 1 to 7. This rating system is based on the average fluctuations of the net asset value over the past five years. It corresponds to the variation range of the portfolio upwards and downwards. If the net asset value is less than 5 years old, the rating is determined by other regulatory calculation methods. Historical data such as those used to calculate the rating may not be a reliable indication of the future risk profile. The current category is neither a guarantee nor an objective. Category 1 does not signify a risk-free investment.

Top